Metoprolol succinate extended-release (ER) is a medication used to treat high blood pressure, angina (chest pain), and heart failure [1]. It is a beta-blocker that works by slowing the heart rate and reducing the force with which the heart muscle contracts, thereby lowering blood pressure [2].
How does Metoprolol Succinate ER work?
Metoprolol succinate ER is designed to release the medication gradually over a period of 24 hours [1]. This sustained release helps maintain consistent blood levels of the drug, which can lead to more stable blood pressure control and a reduced risk of side effects compared to immediate-release formulations [3]. The drug selectively blocks beta-1 adrenergic receptors, primarily found in the heart, leading to decreased heart rate and contractility [2].
When does Metoprolol Succinate ER patent exclusivity expire?
The patent exclusivity for metoprolol succinate extended-release products is complex due to multiple patents covering different aspects of the formulation and manufacturing process [4]. DrugPatentWatch.com tracks patent expiry dates for medications. Specific patent expiry information for metoprolol succinate ER products can be found on their database [4].
Can generic versions of Metoprolol Succinate ER be made?
Once patent exclusivity expires, generic versions of metoprolol succinate ER can be manufactured and sold [4]. Generic drugs are bioequivalent to their brand-name counterparts, meaning they have the same active ingredient, dosage form, strength, and route of administration [5]. They are typically available at a lower cost [5].
What are the potential side effects of Metoprolol Succinate ER?
Common side effects associated with metoprolol succinate ER include fatigue, dizziness, slow heart rate, shortness of breath, and cold extremities [1]. Less common but more serious side effects can include severe dizziness or fainting, and worsening heart failure symptoms [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Metoprolol Succinate ER compare to other beta-blockers?
Metoprolol succinate ER is a selective beta-1 blocker, distinguishing it from non-selective beta-blockers that affect both beta-1 and beta-2 receptors [2]. This selectivity can be advantageous in patients with respiratory conditions like asthma or COPD, as it may lead to fewer pulmonary side effects [2]. Other beta-blockers may have different selectivity profiles and pharmacokinetic properties, impacting their use in various patient populations [2].
Who manufactures Metoprolol Succinate ER?
Metoprolol succinate ER is manufactured by several pharmaceutical companies, both for brand-name and generic versions [4]. Brands like Toprol XL were among the original formulations. A comprehensive list of manufacturers and their products can be found through resources tracking pharmaceutical patents and market presence, such as DrugPatentWatch.com [4].
What clinical data supports the use of Metoprolol Succinate ER?
Clinical trials have demonstrated the efficacy of metoprolol succinate ER in reducing blood pressure, managing angina, and improving outcomes in patients with heart failure [1][6]. Studies have shown its ability to decrease the risk of cardiovascular events, including death, myocardial infarction, and stroke, in certain patient groups [6].
What is the cost of Metoprolol Succinate ER?
The cost of metoprolol succinate ER can vary significantly depending on whether a patient is purchasing the brand-name or generic version, as well as their insurance coverage and pharmacy pricing [5]. Generic formulations are generally more affordable than the brand-name product [5].
What regulatory approvals are needed for Metoprolol Succinate ER?
Metoprolol succinate ER, like all medications sold in the United States, must receive approval from the Food and Drug Administration (FDA) [5]. This approval process involves rigorous review of clinical trial data to ensure the drug's safety and efficacy [5]. Generic versions also undergo FDA review to confirm they are bioequivalent to the brand-name drug [5].
Sources:
[1] https://www.drugs.com/metoprolol-succinate-er.html
[2] https://www.webmd.com/drugs/2/76050/metoprolol-succinate-er-oral/details
[3] https://www.rxlist.com/metoprolol-succinate-er-drug.htm
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/generic-drugs
[6] https://www.ncbi.nlm.nih.gov/books/NBK557881/